Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCBMT12104


Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD)

Principal Investigator(s)

Madan Jagasia


  • Protocol No. VICCBMT12104
  • Open Date: 02/04/2014
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: To define the maximum tolerated dose (MTD) of brentuximab vedotin when given as treatment for steroid-refractory acute GVHD
  • Disease Sites: Leukemia; Multiple Myeloma; Hematologic
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Brentuximab Vedotin
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01596218
  • Secondary Protocol No: 12-094


None Provided.


Ages Eligible for Study:18 Years and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No


Inclusion Criteria:
• Acute GVHD
• Corticosteroid refractory
Exclusion Criteria:
• Pregnant or breastfeeding
• Requiring mechanical ventilation
• Concurrent hepatic VOD
• Have received another study agent within 7 days